Abstract
Positron emission tomography (PET) is a powerful molecular imaging technology with the ability to image and monitor molecular events in vivo and in real time. With the increased application of PET radiopharmaceuticals for imaging physiological and pathological processes in vivo, there is a demand for versatile positron emitters with longer physical and biological half-lives. Traditional PET radionuclides, such as carbon-11 (11C) and fluorine-18 (18F), have relatively short half-lives (20 min and 110 min, respectively). Among the currently available positron emitters, the non-standard radiohalogen iodine-124 (124I) has the longest physical half-life at 4.2 d. This, combined with the well characterized radiochemistry of radioiodine, is contributing to the increasing utility of 124I in investigating slow and complex pharmacokinetic processes in clinical nuclear medicine and small animal PET imaging studies. This review will summarize the progress to date on the potential of 124I as a positron emitting nuclide for molecular imaging purposes, beginning with the production of 124I. Particular emphasis will be placed on the basic radiochemistry as it applies to the production of various 124I-labeled compounds, from small molecules, to biomolecules such as peptides and proteins, and finally to macromolecules like nanoparticles. The review will conclude by highlighting promising future directions in using 124I as a positron emitter in PET radiochemistry and molecular imaging.
Keywords: Iodine-124, molecular imaging, nanoparticles, positron emission tomography, proteins, radiochemistry, in vivo, positron emitters, half-lives, radiohalogen, pharmacokinetic
Medicinal Chemistry
Title: Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Volume: 7 Issue: 5
Author(s): Ann-Marie Chacko and Chaitanya R. Divgi
Affiliation:
Keywords: Iodine-124, molecular imaging, nanoparticles, positron emission tomography, proteins, radiochemistry, in vivo, positron emitters, half-lives, radiohalogen, pharmacokinetic
Abstract: Positron emission tomography (PET) is a powerful molecular imaging technology with the ability to image and monitor molecular events in vivo and in real time. With the increased application of PET radiopharmaceuticals for imaging physiological and pathological processes in vivo, there is a demand for versatile positron emitters with longer physical and biological half-lives. Traditional PET radionuclides, such as carbon-11 (11C) and fluorine-18 (18F), have relatively short half-lives (20 min and 110 min, respectively). Among the currently available positron emitters, the non-standard radiohalogen iodine-124 (124I) has the longest physical half-life at 4.2 d. This, combined with the well characterized radiochemistry of radioiodine, is contributing to the increasing utility of 124I in investigating slow and complex pharmacokinetic processes in clinical nuclear medicine and small animal PET imaging studies. This review will summarize the progress to date on the potential of 124I as a positron emitting nuclide for molecular imaging purposes, beginning with the production of 124I. Particular emphasis will be placed on the basic radiochemistry as it applies to the production of various 124I-labeled compounds, from small molecules, to biomolecules such as peptides and proteins, and finally to macromolecules like nanoparticles. The review will conclude by highlighting promising future directions in using 124I as a positron emitter in PET radiochemistry and molecular imaging.
Export Options
About this article
Cite this article as:
Chacko Ann-Marie and R. Divgi Chaitanya, Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography, Medicinal Chemistry 2011; 7 (5) . https://dx.doi.org/10.2174/157340611796799221
DOI https://dx.doi.org/10.2174/157340611796799221 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Overview of Base Excision Repair Biochemistry
Current Molecular Pharmacology Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology ZIP4 is a Novel Diagnostic and Prognostic Marker in Human Pancreatic Cancer: A Systemic Comparison Between EUS-FNA and Surgical Specimens
Current Molecular Medicine Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery
Current Pharmaceutical Design Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer
Current Gene Therapy Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives
Current Pharmaceutical Design Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry Autotaxin and Lysophosphatidic Acid Receptors as Novel Targets for the Radiosensitization of Tumor Vasculature in Non-Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy